Losses
-€1.1m in five years
Every financial year from 2021 to 2025 closed with a loss. 2023 was the heaviest.
CBX MEDICAL
Lifetime
5 annual accounts with figures on one time axisGross marginpeak -€14,483 (2025)
-€14,483▲ €48,818
Resultlowest -€321,406 (2023)
-€123,673▲ €41,564
Equitypeak €1.1m (2023)
€782,209▼ 17.8%
Debts
€289,520▲ 2.0%
Board9 names since 2020
4 directorsJonathan BLONDIAU and 3 others
Owners2 names in the annual accounts
12.05%Carbon and 1 other
Documentsfilings and deeds
13-07-202618 days before the deadline
2025micro format
Gross margin from -€63,301 to -€14,483Loss of €123,673Resignation: Hayez Jacques (director) 07-01Equity from €952,089 to €782,209Investments €334,137Cash from €225,062 to €16,156
Key points
from the 2025 annual accountsInvestments
€333,033 2.4 × depreciation
Green is investment, beige is depreciation.
Liquidity
1.56 was 3.07 in 2024
Short-term debts rose from €263,826 to €289,520.
Filings
5 annual accounts 2 late
The 2021 accounts came latest: 31 days after the end of the period.
At the same address
48 companies
Position in the sector
-€123,673
Lower net result than 95% of companies in retail trade. Sector median €5,067 · 22,842 companies.
Turnover not published (micro format)
Checked score
68
Healthy
Financially stronger than 39% of micro companies in retail trade (NACE 47)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
0.8% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.6% across 40,273 companies (NACE 47, micro).
About 8 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.5%
01-2025: 0.5%● unchanged vs 12-2024
02-2025: 0.5%● unchanged vs 01-2025
03-2025: 0.5%● unchanged vs 02-2025
04-2025: 0.5%● unchanged vs 03-2025
05-2025: 0.5%● unchanged vs 04-2025
06-2025: 0.6%▲ +0.1 percentage points vs 05-2025
07-2025: 0.6%● unchanged vs 06-2025
08-2025: 0.3%▼ -0.3 percentage points vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025lowest value
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.4%▲ +0.1 percentage points vs 03-2026
05-2026: 0.4%● unchanged vs 04-2026
06-2026: 0.4%● unchanged vs 05-2026
07-2026: 0.5%▲ +0.1 percentage points vs 06-2026
08-2026: 0.8%▲ +0.3 percentage points vs 07-2026
09-2026: 0.8%● unchanged vs 08-2026highest value
10-2026: 0.8%● unchanged vs 09-2026
11-2026: 0.8%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Loss of €123,673, the second in a row (financial year 2025)
Sector: Retail trade (NACE 47)
Liquidity: current ratio 1.56, cash €16,156, halved
lowers risk
Size: total assets €1.1m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 83% of them on solvency, 39% on liquidity, 15% on profitability and 21% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 224 companies had the same profile as CBX MEDICAL has now. Each dot is one company, two years later.
88.4%
were still trading
7.1%
stopped another way
4.0%
went bankrupt
Another 0.4% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of CBX MEDICAL itself is lower: 0.8% within 12 months. It rests on far more data about CBX MEDICAL than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 224 companies, not a prediction for CBX MEDICAL. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €50,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.56 (3.07 in 2024), above the usual 1.5. Short-term debt is 27% and cash 1.5% of total assets. 27% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
2122232425
2021 to 2025 · latest year -€123,673
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 13-07-2026, 18 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
18 days early
2024
20 days early
2023
27 days early
2022
22 days late
2021
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 5 accounts on average 2 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 13 July (4 of the last 5 accounts filed within 40 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
06-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
I
InvestBW
Director, since 05-06-2023
- Carbon 12.05%equity €119.8m (2025) · 30-06-2025 annual accounts of Carbon
- B2START 8.04%equity €4.1m (2025) · 2025 annual accounts of B2START
Recent changes
Appointment: ANDRE, MARBAIX & C° SRL (statutory auditor)
Permanent representative: Martine Marbaix · General meeting of 04-06-2024 · Gazette deed
Resignation: Hayez Jacques (director)
Board meeting of 17-12-2024 · Gazette deed
Resignation: 6K venture capital (director)
Appointment: InvestBW (director) · General meeting of 05-06-2023 · Gazette deed
Permanent representatives: de Halleux Elisabeth and Moulin Maxime
Board meeting of 14-12-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| CBX MEDICAL Charleroi | €1.1m | -€14,483 | 73.0% | - |
| CUSTO BOX Ghent | €0.9m | -€119,611 | 11.8% | - |
| JURIC Gerpinnes | €0.7m | -€26,774 | 4.6% | - |
| SUPLEMINT Lasne | €0.7m | -€65,533 | 19.7% | 2.1 |
| ER-PA Brussel Schaerbeek | €0.9m | -€197,661 | -66.0% | - |
| OENANI Ternat | €1.9m | -€9,983 | -2.9% | - |
| UNITY Beersel | €0.7m | €1,155 | 0.5% | - |
These companies have the same main activity as CBX MEDICAL: other non-specialised retail sale (NACE 47120). They are comparable in size and age: total assets between €657,000 and €1.9m, founded between 2018 and 2021.
Official details
Source: KBO- Status
- Active since 23-07-2020Normal situation
- Registered office
- 49 active companies are registered at this address3 started in the 12 months before. Source: KBO register, as of 6 November 2026.
- Activity
- Other non-specialised retail saleNACE 47120and 3 others
- Joint committee
- 207White-collar workers in the chemical industry · annual accounts 2024
- Establishment units
- 2.307.444.5126000 Charleroi, since 23-07-2020
- 2.309.047.7821180 Uccle, since 01-08-2020
- Financial year end
- 31 December
- Peppol
- Reachable
Annual accounts 2025
- Total assets
- €1.1m▼ 13.3%
- Filing
- Filed on 13-07-2026, 18 days before the end of the filing period
Insights on CBX MEDICAL
CBX MEDICAL files the micro format. That format states no turnover. The gross margin rose from -€143,049 in 2021 to -€14,483 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about CBX MEDICAL
- What is the company number of CBX MEDICAL?
- The company number of CBX MEDICAL is 0750.926.884. The VAT number is the same number with BE in front: BE 0750.926.884.
- Where is CBX MEDICAL based?
- The registered office is at Avenue Général Michel 1E, 6000 Charleroi.Company details
- What does CBX MEDICAL do?
- According to the KBO register, the main activity is other non-specialised retail sale (NACE 47120).
- What is the legal form of CBX MEDICAL?
- CBX MEDICAL is a private limited company (BV).
- When was CBX MEDICAL founded?
- CBX MEDICAL was founded on 23-07-2020.
- Is CBX MEDICAL still active?
- Yes, CBX MEDICAL is an active enterprise in the KBO register.
- How many employees does CBX MEDICAL have?
- CBX MEDICAL had an average of 0.3 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- Which joint committee does CBX MEDICAL fall under?
- In its 2024 annual accounts, CBX MEDICAL states joint committee 207 (White-collar workers in the chemical industry).
- What is the turnover of CBX MEDICAL?
- The annual accounts for financial year 2025 state no turnover. The micro format does not require it.
- Is CBX MEDICAL profitable?
- In financial year 2025, CBX MEDICAL made a loss of €123,673.
- Where can I find the annual accounts of CBX MEDICAL?
- CBX MEDICAL filed 5 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CBX MEDICAL due?
- CBX MEDICAL must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.